{"id":"il-7-il-15-pre-treated-cd19-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an engineered cell therapy where CD19-targeting CAR-T cells are pre-treated with interleukin-7 (IL-7) and interleukin-15 (IL-15) to boost their expansion, survival, and anti-tumor function. IL-7 and IL-15 are cytokines that promote T cell proliferation and memory formation, improving the therapeutic potency of the CAR-T product. The resulting cells recognize and eliminate CD19-expressing B-cell tumors.","oneSentence":"IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:40:41.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma)"}]},"trialDetails":[{"nctId":"NCT04186520","phase":"PHASE1, PHASE2","title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-05-18","conditions":"Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)","enrollment":100},{"nctId":"NCT02992834","phase":"PHASE4","title":"Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma","status":"UNKNOWN","sponsor":"jiangjingting","startDate":"2016-12","conditions":"Lymphoma, B Cell","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IL-7/IL-15 pre-treated CD19 cells","genericName":"IL-7/IL-15 pre-treated CD19 cells","companyName":"jiangjingting","companyId":"jiangjingting","modality":"Biologic","firstApprovalDate":"","aiSummary":"IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies. Used for B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}